Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Covert medication.

Hartshorn M.

J Am Acad Psychiatry Law. 2013;41(1):154. No abstract available.

PMID:
23503186
2.

A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?

McNeil MM, Arana J, Stewart B, Hartshorn M, Hrncir D, Wang H, Lamias M, Locke M, Stamper J, Tokars JI, Engler RJ.

Vaccine. 2012 Mar 23;30(14):2421-6. doi: 10.1016/j.vaccine.2012.01.072. Epub 2012 Feb 3.

PMID:
22310205
3.

Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters.

Mortishire-Smith RJ, Castro-Perez JM, Yu K, Shockcor JP, Goshawk J, Hartshorn MJ, Hill A.

Rapid Commun Mass Spectrom. 2009 Apr;23(7):939-48. doi: 10.1002/rcm.3951.

PMID:
19241416
4.

IsoScore: automated localization of biotransformations by mass spectrometry using product ion scoring of virtual regioisomers.

Leclercq L, Mortishire-Smith RJ, Huisman M, Cuyckens F, Hartshorn MJ, Hill A.

Rapid Commun Mass Spectrom. 2009 Jan;23(1):39-50. doi: 10.1002/rcm.3854.

PMID:
19051234
5.

Protein-ligand docking against non-native protein conformers.

Verdonk ML, Mortenson PN, Hall RJ, Hartshorn MJ, Murray CW.

J Chem Inf Model. 2008 Nov;48(11):2214-25. doi: 10.1021/ci8002254.

PMID:
18954138
6.

Application of fragment screening by X-ray crystallography to beta-secretase.

Murray CW, Callaghan O, Chessari G, Cleasby A, Congreve M, Frederickson M, Hartshorn MJ, McMenamin R, Patel S, Wallis N.

J Med Chem. 2007 Mar 22;50(6):1116-23. Epub 2007 Feb 22.

PMID:
17315856
7.

Diverse, high-quality test set for the validation of protein-ligand docking performance.

Hartshorn MJ, Verdonk ML, Chessari G, Brewerton SC, Mooij WT, Mortenson PN, Murray CW.

J Med Chem. 2007 Feb 22;50(4):726-41.

PMID:
17300160
8.

Automated protein-ligand crystallography for structure-based drug design.

Mooij WT, Hartshorn MJ, Tickle IJ, Sharff AJ, Verdonk ML, Jhoti H.

ChemMedChem. 2006 Aug;1(8):827-38.

PMID:
16902937
9.
10.

Modeling water molecules in protein-ligand docking using GOLD.

Verdonk ML, Chessari G, Cole JC, Hartshorn MJ, Murray CW, Nissink JW, Taylor RD, Taylor R.

J Med Chem. 2005 Oct 6;48(20):6504-15.

PMID:
16190776
11.

Fragment-based lead discovery using X-ray crystallography.

Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H.

J Med Chem. 2005 Jan 27;48(2):403-13.

PMID:
15658854
12.

Cooperative anti-influenza activities of respiratory innate immune proteins and neuraminidase inhibitor.

White MR, Crouch E, van Eijk M, Hartshorn M, Pemberton L, Tornoe I, Holmskov U, Hartshorn KL.

Am J Physiol Lung Cell Mol Physiol. 2005 May;288(5):L831-40. Epub 2004 Dec 17.

13.

Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides.

Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI.

J Biol Inorg Chem. 2004 Dec;9(8):954-60. Epub 2004 Nov 3.

PMID:
15578276
14.

Structure-guided fragment screening for lead discovery.

Verdonk ML, Hartshorn MJ.

Curr Opin Drug Discov Devel. 2004 Jul;7(4):404-10. Review.

PMID:
15338949
15.

Virtual screening using protein-ligand docking: avoiding artificial enrichment.

Verdonk ML, Berdini V, Hartshorn MJ, Mooij WT, Murray CW, Taylor RD, Watson P.

J Chem Inf Comput Sci. 2004 May-Jun;44(3):793-806.

PMID:
15154744
16.

Recognition and management of somatoform disorders.

Brodine AH, Hartshorn MA.

J Prosthet Dent. 2004 Mar;91(3):268-73.

PMID:
15060498
17.

Improved protein-ligand docking using GOLD.

Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD.

Proteins. 2003 Sep 1;52(4):609-23.

PMID:
12910460
18.

AstexViewer: a visualisation aid for structure-based drug design.

Hartshorn MJ.

J Comput Aided Mol Des. 2002 Dec;16(12):871-81.

PMID:
12825620
19.

Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.

Birch L, Murray CW, Hartshorn MJ, Tickle IJ, Verdonk ML.

J Comput Aided Mol Des. 2002 Dec;16(12):855-69.

PMID:
12825619
20.

A web-based platform for virtual screening.

Watson P, Verdonk M, Hartshorn MJ.

J Mol Graph Model. 2003 Sep;22(1):71-82.

PMID:
12798392
21.

A new test set for validating predictions of protein-ligand interaction.

Nissink JW, Murray C, Hartshorn M, Verdonk ML, Cole JC, Taylor R.

Proteins. 2002 Dec 1;49(4):457-71.

PMID:
12402356
22.

3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction.

Goldstein LE, Leopold MC, Huang X, Atwood CS, Saunders AJ, Hartshorn M, Lim JT, Faget KY, Muffat JA, Scarpa RC, Chylack LT Jr, Bowden EF, Tanzi RE, Bush AI.

Biochemistry. 2000 Jun 20;39(24):7266-75.

PMID:
10852726
23.

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI.

J Biol Chem. 1999 Dec 24;274(52):37111-6.

24.

The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction.

Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI.

Biochemistry. 1999 Jun 15;38(24):7609-16.

PMID:
10386999
25.

Protein analyst--a distributed object environment for protein sequence and structure analysis.

Saqi MA, Wild DL, Hartshorn MJ.

Bioinformatics. 1999 Jun;15(6):521-2.

PMID:
10383476
26.

Development and testing of the Resistiveness to Care Scale.

Mahoney EK, Hurley AC, Volicer L, Bell M, Gianotis P, Hartshorn M, Lane P, Lesperance R, MacDonald S, Novakoff L, Rheaume Y, Timms R, Warden V.

Res Nurs Health. 1999 Feb;22(1):27-38.

PMID:
9928961
27.

Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI.

J Biol Chem. 1998 May 22;273(21):12817-26.

28.

Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors.

Huang X, Atwood CS, Moir RD, Hartshorn MA, Vonsattel JP, Tanzi RE, Bush AI.

J Biol Chem. 1997 Oct 17;272(42):26464-70.

29.

Characterization of the electrostatic perturbation of a catalytic site (Cys)-S-/(His)-Im+H ion-pair in one type of serine proteinase architecture by kinetic and computational studies on chemically mutated subtilisin variants.

Plou FJ, Kowlessur D, Malthouse JP, Mellor GW, Hartshorn MJ, Pinitglang S, Patel H, Topham CM, Thomas EW, Verma C, Brocklehurst K.

J Mol Biol. 1996 Apr 19;257(5):1088-111.

PMID:
8632470
30.

Exploring molecular structure by virtual reality.

Hartshorn MJ, Herzyk P, Hubbard RE.

Trends Biotechnol. 1995 Mar;13(3):83-5. No abstract available.

PMID:
7766221
31.

The solution structure of echistatin: evidence for disulphide bond rearrangement in homologous snake toxins.

Cooke RM, Carter BG, Murray-Rust P, Hartshorn MJ, Herzyk P, Hubbard RE.

Protein Eng. 1992 Sep;5(6):473-7.

PMID:
1438157
32.

Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.

Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF.

Nature. 1990 Jul 26;346(6282):362-5.

PMID:
1973824
33.

Immunofluorescent localization of type II insulin-like growth factor receptor in rat liver and hepatoma cells.

Hartshorn MA, Scott CD, Baxter RC.

J Endocrinol. 1989 May;121(2):221-7.

PMID:
2547003
34.

The response of megakaryocytes with processes to thrombin.

Radley JM, Hartshorn MA, Green SL.

Thromb Haemost. 1987 Aug 4;58(2):732-6.

PMID:
3672424
35.

Megakaryocyte fragments and the microtubule coil.

Radley JM, Hartshorn MA.

Blood Cells. 1987;12(3):603-14.

PMID:
3651615
36.

Genetic aspects of misbehavior.

Hartshorn MA.

N Engl J Med. 1970 Nov 5;283(19):1056. No abstract available.

PMID:
5470276
37.
38.

Acid catalysed rearrangements of some 5alpha-acetoxy steroids.

Coxon JM, Hartshorn MP, Lane GA, Richards KE, Senanayake UM.

Steroids. 1969 Oct;14(4):441-7. No abstract available.

PMID:
5344273
39.

Reactions of 3 beta-fluoro-5 alpha-hydroxy steroids.

Coxon JM, Fischer A, Hartshorn MP, Lewis AJ, Richards KE.

Steroids. 1969 Jan;13(1):51-8. No abstract available.

PMID:
5764484
40.

Reactions of epoxides. XVII. "Backbone rearrangements" of cholest-5-ene and 5,6alpha-epoxy-5alpha-cholestane.

Blunt JW, Hartshorn MP, Kirk DN.

Tetrahedron. 1969 Jan;25(1):149-53. No abstract available.

PMID:
5346198
41.

Acid catalysed reactions of alcohols in acetic anhydride.

Fischer A, Hardman MJ, Hartshorn MP, Kirk DN.

Tetrahedron. 1967 Apr;23(4):1647-52. No abstract available.

PMID:
4860123
42.

Reactions of 5-alpha-hydroxy steroids. VII. The westphalen rearrangement of some 3-beta-substituted-6-beta-acetoxy-5-alpha-hydroxy cholestanes.

Fischer A, Hardman MJ, Hartshorn MP, Kirk DN, Thawley AR.

Tetrahedron. 1967 Jan;23(1):159-65. No abstract available.

PMID:
6037279
43.
44.

Studies on a Possible Correlation Between Experimental and Clinical Data Concerning the Response of Infection to Serum.

Chandler CA, Hartshorn M.

Yale J Biol Med. 1933 Jul;5(6):555-8. No abstract available.

Supplemental Content

Loading ...
Support Center